Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2

Donald S. McCorquodale, Gladys Montenegro, Ainsley Peguero, Nicole Carlson, Fiorella Speziani, Justin Price, Sean W. Taylor, Michel Melanson, Jeffery M. Vance, Stephan Züchner

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Charcot-Marie-Tooth (CMT) disease is among the most common inherited neurological disorders. Mutations in the gene mitofusin 2 (MFN2) cause the axonal subtype CMT2A, which has also been shown to be associated with optic atrophy, clinical signs of first motor neuron involvement, and early onset stroke. Mutations in MFN2 account for up to 20-30% of all axonal CMT type 2 cases. To further investigate the prevalence of MFN2 mutations and to add to the genotypic spectrum, we sequenced all exons of MFN2 in a cohort of 39 CMT2 patients. We identified seven variants, four of which are novel. One previously described change was co-inherited with a PMP22 duplication, which itself causes the demyelinating form CMT1A. Another mutation was a novel in frame deletion, which is a rare occurrence in the genotypic spectrum of MFN2 characterized mainly by missense mutations. Our results confirm a MFN2 mutation rate of ~15-20% in CMT2.

Original languageEnglish (US)
Pages (from-to)1234-1239
Number of pages6
JournalJournal of Neurology
Issue number7
StatePublished - Jul 2011


  • Charcot-Marie-Tooth disease
  • CMT2
  • CMT2A
  • Inherited peripheral neuropathies
  • MFN2
  • Mitofusin 2

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2'. Together they form a unique fingerprint.

Cite this